These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18062504)

  • 41. Tolerance of adjuvant letrozole outside of clinical trials.
    Fontaine C; Meulemans A; Huizing M; Collen C; Kaufman L; De Mey J; Bourgain C; Verfaillie G; Lamote J; Sacre R; Schallier D; Neyns B; Vermorken J; De Grève J
    Breast; 2008 Aug; 17(4):376-81. PubMed ID: 18455395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
    Cuppone F; Bria E; Verma S; Pritchard KI; Gandhi S; Carlini P; Milella M; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2008 Jan; 112(2):260-7. PubMed ID: 18041059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant aromatase inhibitors and bone health.
    Chowdhury S; Pickering LM; Ellis PA
    J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.
    Ligibel JA; Winer EP
    Breast Cancer Res; 2005; 7(6):255-7. PubMed ID: 16457700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aromatase inhibitors in the management of early breast cancer.
    Nabholtz JM
    Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aromatase inhibitors and the endometrium.
    Cohen I
    Maturitas; 2008 Apr; 59(4):285-92. PubMed ID: 18448280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 50. Treating elderly patients with hormone sensitive breast cancer: what do the data show?
    Balducci L
    Cancer Treat Rev; 2009 Feb; 35(1):47-56. PubMed ID: 18840391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of aromatase inhibitors' side effects in clinical and experimental studies].
    Kubatka P; Péc M
    Klin Onkol; 2009; 22(3):89-93. PubMed ID: 19708541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Aromatase inhibitors in advanced breast cancer].
    Spinelli GP; Tomao F; Miele E; Pasciuti G; Russillo M; Tomao S
    Recenti Prog Med; 2008 Jan; 99(1):34-8. PubMed ID: 18389871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
    Iwase H
    Breast Cancer; 2008; 15(4):278-90. PubMed ID: 18810576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer.
    Tusquets Trías de Bes I; Tormo SS; Mestres JA
    Biomed Pharmacother; 2009 Jan; 63(1):1-10. PubMed ID: 18539426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Barginear M; Clotfelter A; Poznak CV
    Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are all aromatase inhibitors alike?
    Blackwell KL
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():35-43. PubMed ID: 19101793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The similarities of aromatase inhibitors outweigh the differences.
    Jänicke F
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S7-9. PubMed ID: 18337642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of aromatase inhibitors in endocrine responsive breast cancers.
    Goss P; Wu M
    Breast; 2007 Dec; 16 Suppl 2():S114-9. PubMed ID: 17719783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.